Medical device maker Retractable Technologies' Q2 sales drop on weak EasyPoint needle orders

Retractable Technologies

14/08/2026 22:25

Overview
US medical device maker's Q2 sales fell yr/yr due to timing of EasyPoint needle orders
Operating loss for Q2 remained unchanged from prior year
Net income for Q2 was positive due to $6.4 mln gain on sale of equity securities

Outlook
Company expects cost savings in future periods from April 2026 reduction in force
Company says tariffs may continue to materially impact costs in future periods
Company notes ongoing uncertainty regarding timing of future international orders

Result Drivers
EASYPOINT NEEDLE SALES - Co said lower Q2 sales were primarily due to timing of EasyPoint needle orders, with prior-year period boosted by atypical flu season purchasing patterns
INTERNATIONAL SALES DROP - International revenues and EasyPoint needle sales declined, with ongoing uncertainty about timing of future international orders
TARIFF COST MITIGATION - Co said reduction in tariff costs was due to strategic sourcing and increased domestic production

Company press release: ID:nBw9kvp63a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
$7.2 mln
 
Q2 Operating Income
 
-$5.1 mln
 

Reuters Recommended Reads
Aug 14 - Milestone Scientific Q2 revenue rises 22% on medical segment growth, reaffirms 2026 outlook
Aug 13 - Sensus Healthcare Q2 revenue misses estimates as unit sales fall
Aug 13 - US court backs Trump's power to close 'de minimis' tariff exemption

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)